MAY 22, 2021 8:28 AM PDT

FDA Approves Trials for Ketamine to Treat Parkinson's

WRITTEN BY: Annie Lennon

The US FDA has approved PharmaTher’s Investigational New Drug application to begin Phase 2 clinical trials for ketamine to treat levodopa-induced dyskinesia in patients with Parkinson’s disease. 

Levodopa is an amino acid precursor of dopamine and is commonly used alongside carbidopa, an inhibitor of L-amino acid decarboxylase, to treat Parkinson's disease symptoms including tremor, muscle stiffness and slowness of movement. 

Dyskinesia, characterized by rapid, involuntary and uncontrollable movements distinct from the typical tremors associated with Parkinson's, is a side effect of long-term levodopa use. Around half of the patients treated with the drug develop the condition within five years of initial treatment, and almost all patients develop it within ten years. 

While dyskinesia can be localized to one part of the body, it can also spread to other areas. It can also affect speech, the respiratory tract, and the eye muscles in rare cases. 

The underlying cause of dyskinesia from Levodopa is not currently known. However, it may be the result of fluctuations in dopamine caused by the drug, alongside a loss of dopaminergic neurons seen in those with Parkinson's. 

In a retrospective analysis of patients with Parkinson’s disease, researchers found that those treated with ketamine for pain relief experienced an improvement in dyskinesia symptoms. Other studies have found that ketamine may also be able to treat pain and depression, other symptoms that are frequently found in those with Parkinson’s. 

Having now received approval to commence Phase 2 trials investigating the effects of ketamine on Levodopa-induced dyskinesia, the researchers at PharmaTher plan on recruiting up to 36 subjects across eight clinical sites in the US. They will assess the patients according to changes in the Unified Dyskinesia Rating Scale over 8 weeks. They will also monitor total daily ‘off times’, periods when Parkinson’s symptoms return despite the use of medication, from 24-hour diaries. 

 

Sources: American Parkinson Disease AssociationParkinson's News TodayGlobal Newswire

About the Author
  • Science writer with a keen interest in behavioral biology, consciousness medicine and technology. Her current focus is how the interplay of these fields can create meaningful interactions, products and environments.
You May Also Like
MAY 04, 2021
Cell & Molecular Biology
A Potential Weakness in SARS-CoV-2 is Caught on Video
MAY 04, 2021
A Potential Weakness in SARS-CoV-2 is Caught on Video
You can see the spike protein of the virus in action in this video.
MAY 06, 2021
Drug Discovery & Development
Tweaked Version of Ketamine Could Solve the Opioid Crisis
MAY 06, 2021
Tweaked Version of Ketamine Could Solve the Opioid Crisis
Medications that manage post-operative pain are some of the main entry points to opioid addiction and overdose in the US ...
MAY 22, 2021
Drug Discovery & Development
Drug Combo Treats 86% of Patients with Gout
MAY 22, 2021
Drug Combo Treats 86% of Patients with Gout
Researchers at the University of Michigan have found that a combination of two drugs is twice as effective as current tr ...
JUN 17, 2021
Drug Discovery & Development
FDA Approval of First New Alzheimer's Drug in Two Decades Sparks Controversy
JUN 17, 2021
FDA Approval of First New Alzheimer's Drug in Two Decades Sparks Controversy
The FDA recently approved a new drug known as Adulhelm, or aducanumab, to treat Alzheimer’s disease. The first new ...
JUN 24, 2021
Immunology
Gut-Healing Stem Cells to Treat HIV Infections
JUN 24, 2021
Gut-Healing Stem Cells to Treat HIV Infections
A new study has revealed how stem cells can be used to amplify immune responses to HIV, the virus that causes AIDS. The ...
JUL 12, 2021
Cannabis Sciences
How does CBD Affect Heart Arrhythmia?
JUL 12, 2021
How does CBD Affect Heart Arrhythmia?
Heart arrhythmias happen when the heart beats too fast, too slow, or irregularly. According to the Centers for Dise ...
Loading Comments...